Search - tctmd.com

Displaying 81 - 100 of 102

Sort: Relevancy | Date

Presentation TCT 2016

Low-Risk Studies: Design and Updates II - The PARTNER 3 Low-Risk Trial

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Michael J. Mack

October 30, 2016

Presentation TCT 2016

Low-Risk Studies: Design and Updates I - The UK All-Comer TAVI Study

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Neil E. Moat

October 30, 2016

Presentation TCT 2016

Real-world Requirements and Expectations for TAVR in Lower Risk Patients

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Martin B. Leon

October 30, 2016

Presentation TCT 2016

An Interesting Alternative: The New WikiRecs for TAVR Use in Lower Risk Patients

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Catherine M. Otto

October 30, 2016

Presentation TCT 2016

TAVR 2016: Making the Case For New Patient Subsets (Low Risk, Bicuspid, etc.)

Presenter: Marian C. Hawkey, Patricia Keegan

October 30, 2016

Presentation TVT 2016

Study Design for the PARTNER 3 Low-Risk Trial

Presenter: Martin B. Leon

June 16, 2016

Presentation TVT 2016

Study Design for the EVOLUT R Low-Risk Trial

Presenter: Jeffrey J. Popma

June 16, 2016

Presentation TVT 2016

The Relentless Journey of TAVR to Lower-Risk Patients: Are We There Yet?

Presenter: Martin B. Leon

June 16, 2016

Presentation SOLACI 2016

Future Directions in TAVR: From Moderate-Low Risk Patients to New Devices

Presenter: Martin B. Leon

June 10, 2016

Presentation

TAVR Compared with SAVR in Low-Risk Patients

Presenter: Stefano Rosato

May 16, 2016

Presentation TCT 2015

TCT 79: Efficacy of Cangrelor in Lesions With High-Risk and Low-Risk Angiographic Characteristics The CHAMPION PHOENIX Trial

Presenter: Lisa K. Jennings, Neal S. Kleiman, Gregg W. Stone

October 13, 2015

Presentation TCT 2015

The Case for TAVR Expansion to Lower-Risk Patients

Presenter: Martin B. Leon, Neil E. Moat, Nicolo Piazza

October 11, 2015

Presentation TVT 2015

A Surgeons Perspective: Will the IMPLANTING TEAM Change for Intermediate- and Low-Risk Transfemoral TAVR Patients?

Presenter: Francesco Maisano

June 04, 2015

Presentation TVT 2015

Should the Minimalist Approach Change for Intermediate- and Low-Risk TAVR Patients?

Presenter: Vinayak Bapat

June 04, 2015

Presentation TVT 2015

Making the Case for TAVR Expansion to Lower-Risk Patients!

Presenter: Robert O. Bonow, Martin B. Leon, Jean-Michel Paradis, Nicolo Piazza

June 04, 2015

Presentation TCT 2014

TAVR Is Preferred for All but the Lowest-Risk Patients!

Presenter: Alejandro O. Palacios, Ernesto M. Torresani, Alec S. Vahanian

September 13, 2014

Presentation TCT 2014

CON: A Call for Reason and Restraint!

Presenter: Michael J. Mack

September 13, 2014

Presentation TCT 2014

PRO: It has Already Happened and Is Justified!

Presenter: Nicolo Piazza

September 13, 2014

Presentation TVT 2014

CON: A Call to Reason and Restraint

Presenter: Neil E. Moat

June 05, 2014

Presentation TVT 2014

PRO: It has Already Happened and It's Justified

Presenter: Axel Linke

June 05, 2014

Advertisement

Low-Risk Studies: Design and Updates II - The PARTNER 3 Low-Risk Trial

Low-Risk Studies: Design and Updates I - The UK All-Comer TAVI Study

Real-world Requirements and Expectations for TAVR in Lower Risk Patients

An Interesting Alternative: The New WikiRecs for TAVR Use in Lower Risk Patients

TAVR 2016: Making the Case For New Patient Subsets (Low Risk, Bicuspid, etc.)

Study Design for the PARTNER 3 Low-Risk Trial

Study Design for the EVOLUT R Low-Risk Trial

The Relentless Journey of TAVR to Lower-Risk Patients: Are We There Yet?

Future Directions in TAVR: From Moderate-Low Risk Patients to New Devices

TAVR Compared with SAVR in Low-Risk Patients

TCT 79: Efficacy of Cangrelor in Lesions With High-Risk and Low-Risk Angiographic Characteristics The CHAMPION PHOENIX Trial

The Case for TAVR Expansion to Lower-Risk Patients

A Surgeons Perspective: Will the IMPLANTING TEAM Change for Intermediate- and Low-Risk Transfemoral TAVR Patients?

Should the Minimalist Approach Change for Intermediate- and Low-Risk TAVR Patients?

Making the Case for TAVR Expansion to Lower-Risk Patients!

TAVR Is Preferred for All but the Lowest-Risk Patients!

CON: A Call for Reason and Restraint!

PRO: It has Already Happened and Is Justified!

CON: A Call to Reason and Restraint

PRO: It has Already Happened and It's Justified

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content